NCT00792831View on ClinicalTrials.gov

Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia

PHASE2TerminatedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

ITF2357

Histone-Deacetylase Inhibitor

Trial Locations (1)

06074

Department of Internal Medicine and Public Health, University of Perugia, Perugia

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Italfarmaco

INDUSTRY